VRAX
Virax Biolabs Group
$3.10
−$0.09 (−2.82%)Jul 27, 2026
Key metrics
The numbers that frame VRAX today
- Market cap
- $1.80M
- P/E (TTM)
- -0.4
- EV / FCF
- 0.9
- Gross margin
- 61.9%
- EV / Sales
- -340.4
- ROIC
- -333.4%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $2.50
- 52wk High
- $25.75
Growth
Revenue and earnings trend for VRAX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about VRAX
Is Virax Biolabs Group a good buy?
No. Virax Biolabs Group has poor quality and poor momentum. Both signals point to a weaker setup.
What is the market capitalization of VRAX?
Virax Biolabs Group's market capitalization is $1.80M.
What is the P/E ratio for VRAX stock?
Virax Biolabs Group's current P/E ratio is -0.4.
What is the 52-week high for VRAX stock?
The 52-week high for Virax Biolabs Group is $25.75. The current close of $3.10 is 88% below that high.
What is the 52-week low for VRAX stock?
The 52-week low for Virax Biolabs Group is $2.50. The current close of $3.10 is 24% above that low.
Does VRAX stock pay dividends?
Virax Biolabs Group does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for VRAX?
Virax Biolabs Group's Debt / Equity ratio is 0.06.